Depression - Augmentation or switch after initial SSRI treatment [1]

New England Journal of Medicine

Volumn 354, Issue 24, 2006, Pages 2611-

  Sussman, Norman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

DRUG SUBSTITUTION; HEALTH PRACTITIONER; HUMAN; LETTER; MAJOR DEPRESSION; PRIORITY JOURNAL; REMISSION;

EID: 33745058807     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc066200     Document Type: Letter

References (5)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-42.
2. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-42.
3. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
4. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005;22:68-76.
5. Cipriani A, Brambilla P, Furukawa T, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005;4:CD004185.